Is the survival of melanoma patients receiving polyvalent melanoma cell vaccine linked to the human leukocyte antigen phenotype of patients?

Journal of Clinical Oncology

Volumn 16, Issue 4, 1998, Pages 1430-1437

  Hoon, Dave S B ^a   Okamoto, Tetsuro ^a   Wang, He Jing ^a   Elashoff, Robert ^a   Nizze, Anne J ^a   Foshag, Leland J ^a   Gammon, Guy ^a   Morton, Donald L ^a  

^a JOHN WAYNE CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER VACCINE; HLA A ANTIGEN; HLA ANTIGEN CLASS 1; HLA B ANTIGEN; HLA B35 ANTIGEN; MELANOMA VACCINE; POLYVALENT MELANOMA CELL VACCINE; UNCLASSIFIED DRUG;

ADULT; ALLELE; ANTIGEN EXPRESSION; ARTICLE; CANCER SURVIVAL; CLINICAL TRIAL; DRUG EFFICACY; FEMALE; HLA SYSTEM; HUMAN; IMMUNE RESPONSE; INTRADERMAL DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; MALE; MELANOMA; PHASE 2 CLINICAL TRIAL; PHENOTYPE; PRIORITY JOURNAL; VACCINATION;

EID: 0031925725     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.1998.16.4.1430     Document Type: Article

References (49)

1. Morton DL, Foshag LJ, Hoon DSB, et al: Prolongation of survival in metastatic melanoma after active specific immunotherapy with a new polyvalent melanoma vaccine. Ann Surg 216:463-482, 1992
2. Livingston PO, Wong GYC, Alduri S, et al: Improved survival in stage III melanoma patients with GM2 antibodies: A randomized trial of adjuvant vaccination with GM2 ganglioside. J Clin Oncol 12:1036-1044, 1994
3. Berd D, Maguire HC, McCue P, et al: Treatment of metastatic melanoma with an autologous tumor-cell vaccine: Clinical and immunological results in 64 patients. J Clin Oncol 8:1858-1867, 1992
4. Mitchell MS, Harel W, Kan-Mitchell J, LeMay LG, et al: Active specific immunotherapy of melanoma with allogeneic cell lysates. Rationale, results and possible mechanisms of action. Ann NY Acad Sci 690:153-166, 1993
5. Miller K, Abeles G, Oratz R, et al: Improved survival of patients with melanoma with an antibody response to immunization to a polyvalent melanoma vaccine. Cancer 75:495-502, 1995
6. Morton DL, Hoon DSB, Nizze JA, et al: Polyvalent melanoma vaccine improves survival of patients with metastatic melanoma. Ann NY Acad Sci 690:120-134, 1993
7. Cascinelli N, Foa R, Parmiani G: Active immunization of metastatic melanoma patients with interleukin-4 transduced, allogeneic melanoma cells. A phase I-II study. Hum Gene Ther 5:1059-1064, 1994
8. Wallack MK, Sivanandham M, Balch CM, et al: A phase III randomized, double-blind multiinstitutional trial of vaccinia melanoma oncolysate-active specific immunotherapy for patients with stage II melanoma. Cancer 75:34-42, 1995
9. Hersey P, Werkman H, Edwards AE: Western blot analysis of serological responses following immunization with vaccinia viral lysates of melanoma cells. Int J Cancer 46:612-617, 1990
10. Berthier-Vergnes O, Portoukalian J, Leftheriotis E, et al: Induction of IgG antibodies directed to a M(r)31,000 melanoma antigen in patients immunized with vaccinia virus melanoma oncolysates. Cancer Res 54:2433-2439, 1994
11. Mittelman A, Chen GZJ, Wong GY, et al: Human high molecular weight-melanoma associated antigen mimicry by mouse anti-idiotypic monoclonal antibody MK2-23: Modulation of the immunogenicity in patients with malignant melanoma. Clin Cancer Res 1:705-713, 1995
12. Jaeger E, Bernhard H, Romero P, et al: Generation of cytotoxic T-cell responses with synthetic melanoma-associated peptides in vivo: Implications for tumor vaccines with melanoma-associated antigens. Int J Cancer 66:162-169, 1996
13. Hoon DSB and Irie RF: Current status of human melanoma vaccines. Can they control malignant melanoma? Biodrugs 1:66-84, 1997
14. + cytotoxic T cells by sensitization with allogeneic melanomas bearing shared or cross-reactive HLA-A. Cell Immunol 139:411-425, 1992
15. Morioka N, Kikumoto Y, Hoon DSB, et al: A decapeptide (Gln-Asp-Leu-Thr-Met-Lys-Tyr-Gln-Ile-Phe) from human melanoma is recognized by CTL in melanoma patients. J Immunol 153:5650-5658, 1994
16. Crowley NJ, Darrow TL, Quinn-Allen MA, et al: MHC-restricted recognition of autologous melanoma by tumor-specific cytotoxic T cells. Evidence for restriction by a dominant HLA-A allele. J Immunol 146:1692-1699, 1991
17. Celis E, Tsai V, Crimi C, et al: Induction of anti-tumor cytotoxic T lymphocytes in normal human using primary cultures and synthetic peptide epitopes. Proc Natl Acad Sci USA 91:2105-2109, 1994
18. van der Bruggen P, Traversari C, Chomez P, et al: A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science 254:1643-1647, 1991
19. Rivoltini L, Loftus DJ, Barracchini K, et al: Binding and presentation of peptides derived from melanoma antigens MART-1 and glycoprotein-100 of HLA-A2 subtypes. Implications for peptide-based immunology. J Immunol 156:3882-3891, 1996
20. Peoples GE, Goedegebuure PS, Andrews JVR, et al: HLA-A2 presents shared tumor-associated antigens derived from endogenous proteins in ovarian cancer. J Immunol 151:5481-5491, 1993
21. Morioka N, Kikumoto Y, Hoon DSB, et al: Cytotoxic T cell recognition of a human melanoma derived peptide with a carboxyl-terminal alanine-proline sequence. Mol Immunol 32:573-581, 1995
22. Barbetti AA, Park MS, Terasaki PI, et al: HLA serologic epitopes, in Terasaki PI (ed): Clinical Transplants 1989. Los Angeles, CA, UCLA Tissue Typing Laboratory, 1990, pp 477-498
23. Imanishi T, Gojobori T: Patterns of nucleotide substitutions inferred from the phylogenies of the class I major histocompatibility complex genes. J Mol Evol 35:196-204, 1992
24. Lee TD: Distribution of HLA antigens in North American Caucasians, North American blacks and Orientals, in Lee TD (ed): The HLA System 1990. New York, NY, Springer-Verlag, 1990, pp 141-178
25. Uchiyama A, Hoon DSB, Morisaki T, et al: Transfection of interleukin 2 gene into human melanoma cells augments cellular immune response. Cancer Res 53:949-952, 1993
26. Hayashi Y, Hoon DSB, Foshag LJ, et al: A preclinical model to assess the antigenicity of an HLA-A2 melanoma cell vaccine. Cancer 72:750-759, 1993
27. Hayashi Y, Hoon DSB, Park MS, et al: Cytotoxic T cell lines recognize autologous and allogeneic melanomas with shared or cross-reactive HLA-A. Cancer Immunol Immunother 34:419-423, 1992
28. Egea E, Iglesias A, Salazar M, et al: The cellular basis for lack of antibody response to hepatitis B vaccine in humans. J Exp Med 73:531-538, 1991
29. Alper CA, Kruskall MS, Marcus-Bagley D, et al: Genetic prediction of nonresponse to hepatitis B vaccine. N Engl J Med 321:708-712, 1989
30. Desombre I, Hauser P, Rossau R, et al: Nonresponders to hepatitis B vaccine can present envelope particles to T lymphocytes. J Immunol 154:520-529, 1995
31. Hatae K, Kimura A, Okubo R, et al: Genetic control of nonresponsiveness to hepatitis B virus vaccine by an extended HLA haplotype. Eur J Immunol 22:1899-1905, 1992
32. Stephens HA, Brown AE, Chandanayingyong D, et al: The presence of the HLA class II allele DPB1*0501 in ethnic Thais correlates with an enhanced vaccine-induced antibody response to a malaria sporozoite antigen. Eur J Immunol 25:3142-3147, 1995
33. Marincola FM, Venzon D, White D, et al: HLA association with response and toxicity in melanoma patients treated with interleukin 2-based immunotherapy. Cancer Res 52:6561-6566, 1992 (errata, 53:3846, 6079, 1993)
34. Mitchell MS, Harel W, Groshen S: Association of HLA phenotype with response to active specific immunotherapy of melanoma. J Clin Oncol 10:1158-1164, 1992
35. Neter J, Wasserman W, Kutner MH: Applied Linear Statistical Methods. Boston, MA, Irwin, 1990
36. Morton DL, Wong JH, Kirkwood JM, et al: Malignant melanoma, in Holland, JF, Frei E III, Basr RC Jr, et al (eds): Cancer Medicine, vol 2. Philadelphia, PA, Lea & Febiger, 1993, pp 1793-1824
37. Wanek LA, Elashoff RM, Goradia TM, et al: Application of multistage Markov modeling to malignant melanoma progression. Cancer 73:336-343, 1994
38. Herman J, Van der Bruggen P, Luescher IF, et al: A peptide encoded by the human MAGE3 gene and presented by HLA-B44 induces cytolytic T lymphocytes that recognize tumor cell expressing MAGE3. Immunogenetics 43:377-383, 1996
39. Brichard VG, Herman J, Van Pel A, et al: A tyrosinase nanopeptide presented by HLA-B44 is recognized on a hyman melanoma by autologous cytolytic T lymphocytes. Eur J Immunol 26:224-230, 1996
40. 2-microglobulin gene-null FO-1 melanoma cells. Cancer Res 53:4303-4309, 1993
41. Rivoltini L, Barracchini KC, Viggiano V, et al: Quantitative correlation between HLA class I allele expression and recognition of melanoma cells by antigen-specific cytotoxic T lymphocytes. Cancer Res 55:3149-3157, 1995
42. Van Duinen SG, Ruiter DJ, Broecker EB, et al: Level of HLA antigens in locoregional metastases and clinical course of the disease in patients with melanoma. Cancer Res 48:1019-1025, 1988
43. Rammensee HG, Friede T, Stevanovic S: MHC ligands and peptide motifs: First listing. Immunogenetics 41:178-228, 1995
44. Hoon DSB, Banez M, Okun E, et al: Modulation of human melanoma cells by interleukin-4 and in combination with γ-interferon or α-tumor necrosis factor. Cancer Res 51:2002-2008, 1991
45. Hoon DSB, Hayashi Y, Morisaki T, et al: Interleukin-4 plus tumor necrosis factor α augments the antigenicity of melanoma cells. Cancer Immunol Immunother 37:378-384, 1993
46. Maio M, Gulwani B, Morgano A, et al: Differential modulation by tumor necrosis factor and immune interferon of HLA class-II antigens expressed by melanoma cells. Int J Cancer 44:554-559, 1989
47. Romero P, Pannetier C, Herman J, et al: Multiple specificities in the repertoire of a melanoma patient's cytolytic T lymphocytes directed against tumor antigen MAGE-1. J Exp Med 182:1019-1028, 1995
48. Toes TRM, Blom RJJ, van der Voort E, et al: Protective antitumor immunity induced by immunization with completely allogeneic tumor cells. Cancer Res 56:3782-3787, 1996
49. Westby M, Manca F, Dagleish AG: The role of host immune response in determining the outcome of HIV infection. Immunol Today 120:120-126, 1996